Management & Regulatory

Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?
Management & Regulatory Are Zenas Biopharma and Biren Technology Leading the IPO Market Revival?

The IPO market has faced significant turmoil over the past few years, with many companies postponing or canceling their public offering plans due to weak market conditions. However, recent developments indicate a promising shift. Companies like Zenas Biopharma and Biren Technology are making

Sanofi Boosts Beyfortus Output for RSV Season with FDA Approval
Management & Regulatory Sanofi Boosts Beyfortus Output for RSV Season with FDA Approval

Sanofi is gearing up to address the rising demand for its respiratory syncytial virus (RSV) antibody drug, Beyfortus, by leveraging a recently approved manufacturing line. The company's proactive measures aim to ensure that there is no repeat of last year's shortages, which created

Are Biopharma Hedge Funds the Key to Outperforming the Market?
Management & Regulatory Are Biopharma Hedge Funds the Key to Outperforming the Market?

Investors often seek avenues that can offer significant returns while mitigating risks. The biopharma sector, with its blend of innovation and high stakes, has captured the attention of hedge fund managers and investors alike. But can biopharma hedge funds truly be the key to outperforming the

How Is Bain Shaping Biotech with Its New $3 Billion Fund?
Management & Regulatory How Is Bain Shaping Biotech with Its New $3 Billion Fund?

Bain Capital Life Sciences has made headlines with the closure of its new $3 billion biotech fund, the largest in its seven-year history. This monumental step aligns with the firm's continuous efforts since its inception in 2016 to bolster the biotech sector by funding ventures that address

Allspring Significantly Increases Stake in Xeris Biopharma Holdings
Management & Regulatory Allspring Significantly Increases Stake in Xeris Biopharma Holdings

In a notable turn of events, Allspring Global Investments Holdings LLC has dramatically boosted its stake in Xeris Biopharma Holdings, a leading biopharmaceutical company known for its innovative therapies for patients with unmet medical needs. Documented in the latest Form 13F filing with the

Aligos Therapeutics' Reverse Stock Split to Retain Nasdaq Listing
Management & Regulatory Aligos Therapeutics' Reverse Stock Split to Retain Nasdaq Listing

In a determined effort to adhere to Nasdaq listing requirements and secure its position in a competitive market, Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, has executed a 1-for-25 reverse stock split. Effective August 19, 2024, this strategic maneuver aims to elevate the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later